Do you want to read an article? Please log in or register.
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME
Heart Failure
Related content
Atrial FibrillationHeart Failure
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial
Eur J Heart Fail.
Böhm M, Slawik J, Brueckmann M, Mattheus M, George JT, Ofstad AP, Inzucchi SE, Fitchett D, Anker SD, Marx N, Wanner C, Zinman B, Verma S
doi: 10.1002/ejhf.1663.
Heart Failure
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial
ESC Heart Fail
Fitchett D, Inzucchi SE, Zinman B, Wanner C, Schumacher M, Schmoor C, Ohneberg K, Ofstad AP, Salsali A, George JT, Hantel S, Bluhmki E, Lachin JM, Zannad F
doi: 10.1002/ehf2.13615
RECOMMENDED
Heart Failure
Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Eur J Heart Fail.
Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, van Eck JWM, Heerspink HJL, Voors AA
doi: 10.1002/ejhf.1713.
Heart Failure
Use of diuretics and outcomes in patients with type 2 diabetes: Findings from the EMPA-REG OUTCOME trial
Eur J Heart Fail
Pellicori P, Fitchett D, Kosiborod M, Ofstad AP, Seman L, Zinman B, Zwiener I, Wanner C, George J, Inzucchi SE, Testani J, Cleland JGF
doi: 10.1002/ejhf.2220
Atrial FibrillationHeart FailureHypertension
Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry
Eur J Heart Fail.
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G
doi: 10.1002/ejhf.813.
Heart Failure
Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT
Eur J Heart Fail.
Böhm M, Komajda M, Borer JS, Ford I, Maack C, Tavazzi L, Moyne A, Swedberg K; SHIFT Investigators
doi: 10.1002/ejhf.1021.
Heart, Artery and Coronary DiseasesHeart Failure
Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial
Eur J Heart Fail.
Greene SJ, Butler J, Fonarow GC, Subacius HP, Ambrosy AP, Vaduganathan M, Triggiani M, Solomon SD, Lewis EF, Maggioni AP, Böhm M, Chioncel O, Nodari S, Senni M, Zannad F, Gheorghiade M; ASTRONAUT Investigators and Coordinators
doi: 10.1002/ejhf.1019.
Heart FailureHypertensionThrombosis and Stroke
Heart Failure Increases the Risk of Adverse Renal Outcomes in Patients With Normal Kidney Function
Circ Heart Fail.
George LK, Koshy SKG, Molnar MZ, Thomas F, Lu JL, Kalantar-Zadeh K, Kovesdy CP
doi: 10.1161/
Cardiovascular Risk and Diseases
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial
Eur Heart J.
Fitchett D, Inzucchi SE, Wanner C, Mattheus M, George JT, Vedin O, Zinman B, Johansen OE
doi: 10.1093/eurheartj/ehz621.